357 related articles for article (PubMed ID: 32279279)
1. The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro. Evaluation of potential metabolic interactions.
Danek PJ; Wójcikowski J; Daniel WA
Pharmacol Rep; 2020 Dec; 72(6):1685-1694. PubMed ID: 32279279
[TBL] [Abstract][Full Text] [Related]
2. In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions.
Wójcikowski J; Danek PJ; Basińska-Ziobroń A; Pukło R; Daniel WA
Pharmacol Rep; 2020 Jun; 72(3):612-621. PubMed ID: 32219694
[TBL] [Abstract][Full Text] [Related]
3. Asenapine and iloperidone decrease the expression of major cytochrome P450 enzymes CYP1A2 and CYP3A4 in human hepatocytes. A significance for drug-drug interactions during combined therapy.
Danek PJ; Wójcikowski J; Daniel WA
Toxicol Appl Pharmacol; 2020 Nov; 406():115239. PubMed ID: 32941854
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human cytochrome P450 isoenzymes by a phenothiazine neuroleptic levomepromazine: An in vitro study.
Basińska-Ziobroń A; Daniel WA; Wójcikowski J
Pharmacol Rep; 2015 Dec; 67(6):1178-82. PubMed ID: 26481538
[TBL] [Abstract][Full Text] [Related]
5. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
[TBL] [Abstract][Full Text] [Related]
6. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
Wen X; Wang JS; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
[TBL] [Abstract][Full Text] [Related]
7. Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism--an in vitro study.
Wójcikowski J; Daniel WA
Pharmacol Rep; 2009; 61(5):851-8. PubMed ID: 19904008
[TBL] [Abstract][Full Text] [Related]
8. Effect of Naltrexone Hydrochloride on Cytochrome P450 1A2, 2C9, 2D6, and 3A4 Activity in Human Liver Microsomes.
AlRabiah H; Ahad A; Mostafa GAE; Al-Jenoobi FI
Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):707-713. PubMed ID: 29744741
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
11. Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs.
Nakajima M; Nakamura S; Tokudome S; Shimada N; Yamazaki H; Yokoi T
Drug Metab Dispos; 1999 Dec; 27(12):1381-91. PubMed ID: 10570018
[TBL] [Abstract][Full Text] [Related]
12. Effects of phenothiazine neuroleptics on the rate of caffeine demethylation and hydroxylation in the rat liver.
Daniel WA; Syrek M; Ryłko Z; Kot M
Pol J Pharmacol; 2001; 53(6):615-21. PubMed ID: 11985335
[TBL] [Abstract][Full Text] [Related]
13. Influence of classic and atypical neuroleptics on caffeine oxidation in rat liver microsomes.
Daniel WA; Kot M; Wójcikowski J
Pol J Pharmacol; 2003; 55(6):1055-61. PubMed ID: 14730101
[TBL] [Abstract][Full Text] [Related]
14. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes.
Cohen LH; van Leeuwen RE; van Thiel GC; van Pelt JF; Yap SH
Biopharm Drug Dispos; 2000 Dec; 21(9):353-64. PubMed ID: 11523064
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions.
Katoh M; Nakajima M; Shimada N; Yamazaki H; Yokoi T
Eur J Clin Pharmacol; 2000; 55(11-12):843-52. PubMed ID: 10805063
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory Effects of Aschantin on Cytochrome P450 and Uridine 5'-diphospho-glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.
Kwon SS; Kim JH; Jeong HU; Cho YY; Oh SR; Lee HS
Molecules; 2016 Apr; 21(5):. PubMed ID: 27128896
[TBL] [Abstract][Full Text] [Related]
17. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.
Prakash C; Kamel A; Cui D; Whalen RD; Miceli JJ; Tweedie D
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):35S-42S. PubMed ID: 10771452
[TBL] [Abstract][Full Text] [Related]
18. The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes.
Wójcikowski J; Pichard-Garcia L; Maurel P; Daniel WA
Eur Neuropsychopharmacol; 2004 May; 14(3):199-208. PubMed ID: 15056479
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory Effects of Dimethyllirioresinol, Epimagnolin A, Eudesmin, Fargesin, and Magnolin on Cytochrome P450 Enzyme Activities in Human Liver Microsomes.
Kim JH; Kwon SS; Jeong HU; Lee HS
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28468305
[TBL] [Abstract][Full Text] [Related]
20. Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes.
Taavitsainen P; Anttila M; Nyman L; Karnani H; Salonen JS; Pelkonen O
Pharmacol Toxicol; 2000 May; 86(5):215-21. PubMed ID: 10862503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
